ArticleInfection
Enhanced killing of methicillin-resistant Staphylococcus aureus in human macrophages by liposome-entrapped vancomycin and teicoplanin.
Article in Infection. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 78 citations in OpenAlex.
- A Comprehensive Review of Nanomaterials as Potential Weapons against Multidrug-resistantPharmaceutical nanotechnology · 2025Review
- Advancements in Nanoparticle-Based Strategies for Enhanced Antibacterial Interventions.Cell biochemistry and biophysics · 2024Review
- Exploring Nanotechnology as a Strategy to Circumvent Antimicrobial Resistance in Bone and Joint Infections.ACS omega · 2023Review
- Microbial resistance to nanotechnologies: An important but understudied consideration using antimicrobial nanotechnologies in orthopaedic implants.Bioactive materials · 2022Review
- Lipid-based nanosystems for targeting bone implant-associated infections: current approaches and future endeavors.Drug delivery and translational research · 2021Review
- Novel approaches for the treatment of methicillin-resistant Staphylococcus aureus: Using nanoparticles to overcome multidrug resistance.Drug discovery today · 2021Review
- Multi-functionalized nanocarriers targeting bacterial reservoirs to overcome challenges of multi drug-resistance.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020Review
- Antibiotic-Derived Lipid Nanoparticles to Treat IntracellularACS applied bio materials · 2019Article
- Recent insights on nanomedicine for augmented infection control.International journal of nanomedicine · 2019Review
- Anti-Methicillin-ResistantFrontiers in pharmacology · 2019Review
- Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens.Advanced healthcare materials · 2018Review
- Emerging Nanomedicine Therapies to Counter the Rise of Methicillin-Resistant Staphylococcus aureus.Materials (Basel, Switzerland) · 2018Review
- Self-enhanced targeted delivery of a cell wall- and membrane-active antibiotics, daptomycin, against staphylococcal pneumonia.Acta pharmaceutica Sinica. B · 2016Article
- Novel formulations for antimicrobial peptides.International journal of molecular sciences · 2014Review
- Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases.Advanced drug delivery reviews · 2013Review
- Development and stability studies of novel liposomal vancomycin formulations.ISRN pharmaceutics · 2012Article
- PEGylated liposome encapsulation increases the lung tissue concentration of vancomycin.Antimicrobial agents and chemotherapy · 2011Article
- Nanoparticles: Emerging carriers for drug delivery.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2011Article
- Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation.Antimicrobial agents and chemotherapy · 1998Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antibacterial effects of liposomal vancomycin and teicoplanin against intracellular methicillin-resistant Staphylococcus aureus (MRSA) were evaluated using a macrophage infection model. Human blood-derived monocytes were cultured for 7 days to obtain adherent macrophages. Uptake of each drug by macrophages was markedly enhanced by liposomal encapsulation. Following phagocytosis and removal of residual extracellular MRSA, the infected macrophages were exposed to clinically achievable concentrations of teicoplanin and vancomycin. The free (untrapped) and liposome-entrapped forms of each drug were used at the same concentration. The number of intracellular surviving bacteria was determined by colony counts after lysis of the macrophages at different time intervals following drug treatment. Intracellular antimicrobial effect of each drug was significantly (p < 0.001) increased by entrapment in liposomes. Also, the efficacies of the free and liposomal forms of both drugs were correspondingly comparable (p > 0.05). It is, therefore, concluded that liposomal encapsulation of vancomycin and teicoplanin results in an increased availability of the antibiotics for efficient elimination of intracellular MRSA infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.